Browse studies

Find your next paid study

1,002 recruiting studies matching your filters

Phase I/II Dose Escalation & Dose Optimization Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD8359, a CD8-guided T Cell-engaging Antibody That Targets STEAP2, in Adult Participants With Prostate Cancer

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer calle…

Metastatic Prostate Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT07529717

Phase 2

A Double-Blind Phase II Randomized Study of Adaptively Delivered LINAC-Based Stereotactic Radiation for Volatile Brain Metastases With Same-Day Planning and Margin Reduction

The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval …

Brain Metastases, AdultBrain Tumor - MetastaticBrain Metastases From Non-small Cell Lung Cancer (NSCLC)+1 more

Estimated

~$10 – $7,500

Ayal A. Aizer, MDNCT07132190

Phase 1

A Phase 1 Dose-Escalation Study of NPX372, a Bispecific Antibody Targeting B7-H7 and CD3, in Selected Solid Tumor Malignancies

NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the…

Metastatic Malignant Neoplasm

Estimated

~$10 – $8,750

NextPoint Therapeutics, Inc.NCT07563829

Phase 1

A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or met…

Advanced Prostate CancerMetastatic Prostate Cancer

Estimated

~$10 – $8,750

Genentech, Inc.NCT05800665

Observational

Evaluating a Patient Navigation Program to Improve Therapy Management for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

The goal of this study is to test a novel nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer (mBC) receiving tucatinib, t…

HER2+ Metastatic Breast Cancer (MBC)

Estimated

~$10 – $6,250

Duke UniversityNCT06983691

Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma

The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with…

High Grade GliomaDiffuse Intrinsic Pontine GliomaAnaplastic Astrocytoma+6 more

Estimated

~$10 – $750

Nationwide Children's HospitalNCT05839379

Phase 1

An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4/BRG1 Alterations

The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with …

Metastatic Solid TumorAdvanced Solid TumorNon-small Cell Lung Cancer+1 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT06561685

Phase 3

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-F…

Metastatic Colorectal Cancer (CRC)

Estimated

~$10 – $8,750

Summit TherapeuticsNCT07228832

Phase 3

A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compare…

Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more

Estimated

~$10 – $8,750

Revolution Medicines, Inc.NCT07805954

Phase 2

Phase II Clinical Trial Evaluating the Safety and Efficacy of Low Dose Naltrexone (LDN) for the Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer. All men in…

Metastatic Prostate Cancer

Estimated

~$10 – $6,250

University of ArkansasNCT07224009

Phase 2

A Multicenter, Open-label, Randomized Phase 2 Study Evaluating Continuous Weekly Dosing of Ficerafusp Alfa (BCA101) in Combination With Pembrolizumab Versus an Alternative Ficerafusp Alfa Dosing Regimen for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). The study aims to demons…

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma

Estimated

~$10 – $8,750

Bicara TherapeuticsNCT07807163

Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (INTERCEPTioN for Suspected Lung Cancer)for Suspected Lung Cancer)

This study evaluates the effectiveness of tumor samples in providing information about hereditary or cancer specific genetic variants that may have a role in d…

Lung CarcinomaMetastatic Malignant Neoplasm in the Lung

Estimated

~$10 – $750

Mayo ClinicNCT06482073